Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases. by Ruffmann, C et al.
 1
TITLE: Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of 
dementia in Lewy body diseases  
 
Running Head: Neuropathology of dementia in the Lewy body disease spectrum 
 
AUTHORS: Claudio Ruffmann, MD1,2*, Federico C.F. Calboli, PhD1*, Ilaria Bravi, MD3, 
Djordje Gveric, MD, PhD3, Lisa K. Curry, MSc1, Adam de Smith, PhD5,6, Stelios Pavlou5,7, 
Jessica L Buxton, PhD4, Alexandra I.F. Blakemore, PhD4, Petros Takousis, PhD5, Sophie 
Molloy, MD, FRCP3, Paola Piccini, FRCP, PhD3, David T. Dexter, PhD3, Federico 
Roncaroli, MD3, Steve M. Gentleman, PhD3 and Lefkos T. Middleton, MD, FRCP1. 
 
*
 These authors contributed equally 
1
 Neuroepidemiology and Ageing Research Unit, School of Public Health, Imperial College 
London 
 
2
 Centro Parkinson, Istituti Clinici di Perfezionamento di Milano, Italy 
3
 Division of Brain Sciences, Department of Medicine, Imperial College, London 
 
4
 Section of Investigative Medicine, Department of Medicine, Imperial College London 
 
5
 Genomics of Common Disease, School of Public Health, Imperial College London  
 
6 Department of Epidemiology and Biostatistics, University of California, San Francisco, 
San Francisco, CA, USA. 
 
7 Department of Molecular Virology, Cyprus Institute of Neurology and Genetics 
 
 
Corresponding Author:  
 
Dr. Claudio Ruffmann 
Department of Neuropathology 
University of Oxford 
Level 1, West Wing, John Radcliffe Hospital  
Oxford OX3 7PD 
UK 
Tel: +44 01865223047 
Email: claudio.ruffmann@ndcn.ox.ac.uk  
 
KEYWORDS: Parkinson’s disease; Lewy Bodies; Dementia; Aβ;  Neuropathology; alpha-
synuclein 
 
Word Count 
Abstract: 245; Main Body: 3850; Acknowledgements: 133 
 
Number of Figures: 5   Number of Tables: 4 
 
 2
ABSTRACT 
Aims: Our main objective was to determine the neuropathological correlates of dementia 
in patients with Lewy body disease (LBD). Furthermore, we used data derived from 
clinical, neuropathological and genetic studies to investigate boundary issues between 
Dementia with Lewy bodies (DLB) and Parkinson’s disease with (PDD) and without 
(PDND) dementia.   
Methods: 121 cases with a neuropathological diagnosis of LBD and clinical information on 
dementia status were included in the analysis (55 PDD, 17 DLB and 49 PDND). We 
carried out topographical and semi-quantitative assessment of Lewy bodies (LB), Aβ 
plaques and tau-positive neuropil threads (NT). The APOE genotype and MAPT haplotype 
status were also determined.  
Results: The cortical LB (CLB) burden was the only independent predictor of dementia 
(OR: 4.12, p<0.001). The total cortical Aβ plaque burden was an independent predictor of 
a shorter latency to dementia from onset of motor signs (p=0.001). DLB cases had a 
higher LB burden in the parietal and temporal cortex, compared to PDD. Carrying at least 
one APOE ϵ4 allele was associated with a higher cortical LB burden (p=0.02), particularly 
in the neocortical frontal, parietal, and temporal regions.   
Conclusions: High CLB burden is a key neuropathological substrate of dementia in LBD.  
Elevated cortical LB pathology and Aβ plaques are both correlated with a faster 
progression to dementia. The higher LB load in the temporal and parietal regions, which 
distinguishes DLB cases, could have a role in the shorter latency to dementia and may be 
mediated by the APOE ϵ4 allele.  
 
Abbreviations: 
Aβ: Beta-amyloid  
αSN: Alpha-synuclein 
AC: Anterior Cingulate Cortex  
AD: Alzheimer’s disease 
APOE: Apolipoprotein-E 
BNE: BrainNet Europe 
CLB: Cortical Lewy bodies 
CVP: Concomitant Vascular Pathology 
DLB: Dementia with Lewy Bodies 
EC: Entorhinal Cortex 
LB: Lewy bodies 
LBD: Lewy Body disease 
MAPT: Microtubule associated protein tau 
PC: Parietal Cortex 
PD: Parkinson’s disease 
PDD: Parkinson’s disease with dementia 
PDND: Parkinson’s disease without dementia 
NT: Neuropil threads 
SFC: Superior Frontal Cortex 
SNP: Single Nucleotide Polymorphism  
TC: Temporal Cortex 
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INTRODUCTION 
 
Dementia with Lewy Bodies (DLB) represents the second most frequent 
neurodegenerative form of late-onset dementia after Alzheimer’s disease (AD), with a 
yearly incidence of 3.2% of all new dementia cases.1-2 Dementia is also a common non-
motor complication in the course of Parkinson’s disease (PD), where it is known as 
“Parkinson’s disease dementia” (PDD).3 The estimated incidence of PDD in prevalence 
samples of PD reaches 100 per 100,000 patient- years,4 and the cumulative prevalence of 
dementia in patients with PD may exceed 75% in the course of their disease.5 The 
distinction between DLB and PDD is made on clinical grounds, with the arbitrary cut-off of 
dementia occurring before or within one year of motor signs of parkinsonism in DLB.1,6 
DLB, PDD and PD without dementia (PDND) share a common neuropathological substrate 
of alpha-synuclein (αSN) containing intra-neuronal inclusions called Lewy bodies (LB)1,7 
and have been labelled as “Lewy Body Diseases” (LBD).8-10 There is growing evidence 
from several clinic-based11-14 and population-based15 studies of a strong association 
between neocortical αSN/LB pathology and cognitive decline/dementia, although this has 
not been  a consistent finding.16-17 Of note, a variable load of cortical and sub-cortical LB 
has been reported in autopsies of 11-18 % of asymptomatic elderly individuals, a condition 
termed as “Incidental Lewy body disease”, which has been reported to represent a pre-
symptomatic disease stage.18-19  
Recent studies have also shown a positive association between AD-type pathology and 
DLB/PDD. Higher Braak tau stages have been reported in PDD14,20-22 and Aβ plaque 
deposition has been reported in PDD in most20 or a subset of patients.14,23  Other studies 
have reported a higher Aβ plaque burden in DLB compared to both PDD and PDND 
patients in the neocortex21,24-26 and in the striatum27-28 and in both PDD and DLB cases 
compared to PD patients without dementia.29 These observations led to suggestions that 
AD-type Aβ plaques and tau aggregates may also be important correlates of dementia in 
at least a significant portion of LBD patients,21-22,30 that their presence may obscure a 
unique LB-related cognitive phenotype,6 or that they must be present with CLB for 
dementia to occur.31  
A positive correlation has been reported in LBD between the severity of αSN and tau 
pathologies,12,21 αSN and Aβ plaque deposition12,32-35 and between the three pathologies of 
tau, Aβ and αSN.20,22 These observations, coupled with evidence from molecular and in 
vitro studies, have led to the hypothesis of a synergistic interaction12,20 or an additive 
effect15 of the two pathologies at the molecular level. However, others have found no 
difference in CLB counts between PDD cases with and without concomitant AD 
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pathology23 and no significant association between LB, Aβ or tau pathological scores in 22 
prospectively followed patients.11 Several workers have proposed a classification of DLB 
and PDD based on the presence or absence of co-morbid AD-type pathology into DLB and 
PDD with AD pathology (DLB+AD and PDD+AD), as opposed to the “pure synucleopathic” 
forms (devoid of significant AD pathology) of pure DLB (pDLB) and PDD-AD.15,16,23,26,36 
From a genetic standpoint, there have been reports of association between a faster 
cognitive decline and dementia in PD with the H1/H1 haplotype  of the MAPT gene37-38 and 
of H1/H1 with αSN (but not tau) deposition in DLB35,39 but not in PDD.14,20  The  APOE ϵ4 
allele, still the most validated susceptibility genetic factor for AD40 and strongly associated 
with AD pathology,41-43 has recently been reported to also have a significant association 
with  DLB36,41,44 and with PDD in some14,36,45,47 but not all47-48 studies. A higher CLB burden 
has been reported in carriers of the APOE ϵ4 allele14,33,49 but this finding has not been 
confirmed by others.20 
Although a considerable volume of data has been accumulated in recent years there is 
still uncertainty regarding the relationship between the neuropathology and clinical 
presentation due to the  heterogeneity in sample size of cohorts, clinical criteria for 
recruitment and staining methodologies applied by different researchers. This study was 
designed to address these limitations by combining extensive neuropathological semi-
quantitative assessment of αSN, tau and Aβ pathology with genetic characterization of 
APOE and MAPT status in one large sample of LBD patients with and without dementia of 
the DLB and PDD types. Importantly, selection of cases for our sample was based purely 
on neuropathological criteria, making this cohort unbiased for the presence of dementia.  
 
 
 
SUBJECTS AND METHODS 
 
All subjects were donors of brain tissue to the Parkinson UK Brain Bank at Imperial 
College London who had provided informed, written consent for inclusion in scientific 
research studies. Selection for this study was based on a neuropathological diagnosis of 
PD and the availability of reliable clinical data on the presence or absence of dementia. A 
retrospective review of patient medical records was conducted by a team of neurologists 
with expertise in movement disorders (CR, SM, PP, and LTM) to establish the clinical 
diagnosis of PD [20] and classify subjects into (1) PD without dementia within a year prior 
to death (PDND); (2) DLB and (3) PDD. The Diagnostic and Statistical Manual of the 
American Psychiatric Association (4th edition) DSM IV criteria50 and the Clinical Diagnostic 
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Criteria for dementia associated with Parkinson’s disease3 were applied. Cases were 
classified as DLB when dementia occurred prior to or within one year of the onset of motor 
signs (although none actually had dementia onset prior to motor symptoms), whilst cases 
were defined as PDD if dementia occurred later in the disease course.1,3 121 cases were 
included in the analysis (17 DLB, 55 PDD, 49 PDND).  
 
Neuropathological assessment  
 
Topographical staging of αSN pathology was based on the Brain-Net Europe (BNE) 
Consortium guidelines for Braak staging (0-VI).51 Semi-quantitative assessment of LB 
pathology was carried out in five cortical regions: superior frontal cortex (SFC), n = 121; 
inferior and middle temporal cortex (TC), n = 91; parietal cortex, sampled approximately 1 
cm posterior to the central sulcus (PC), n = 84; entorhinal cortex (EC), n= 115; anterior 
cingulate (AC), n = 109. We used a score range of 0-4, as recommended by the DLB 
Consortium.1 For each case, a score representing the average of the individual cortical 
regions was also calculated (mean Cortical LB score).  
On the basis of severity and topographical distribution, neurofibrillary tangle (NT) 
pathology was divided into three categories (mild, moderate and severe) corresponding 
respectively to Braak stages I-II, III-IV, and V-VI of the BNE guidelines.52  
Semi-quantitative assessment of Aβ deposition was performed in the frontal and 
entorhinal cortex with categories of 0 = absent, 1 = mild; 2 = moderate and 3= severe Aβ 
deposition. The individual scores were assigned by subjective assessment of the overall 
stained area in sections of entorhinal and frontal cortex. No distinction was made between 
cored and diffuse plaques. Neither subpial nor intracytoplasmic staining were considered 
for grading (see supplementary figure 1). For data analysis, both the individual cortical Aβ 
plaque score from the frontal and entorhinal regions and the sum of scores from both 
regions (total Cortical Aβ score) were used. Due to the high collinearity between frontal 
and entorhinal Aβ scores within the same subject (Pearson product-moment correlation 
0.870; 95%CI 0.818 – 0.908), for the multivariate model we used total cortical Aβ score, 
which offered a wider range of assessment of overall cortical Aβ burden.  
Vascular pathology was evaluated through retrospective review of the 
neuropathological reports, based on recently proposed criteria;53 cases were categorically 
classified as ‘without’ or ‘with’ concomitant vascular pathology (CVP).  
For more information on methods see the ‘Online Supporting Information’. 
 
Genetic Characterization 
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For all individuals, DNA was extracted from 25 to 50 mg of brain tissue. Six MAPT and 
2 APOE SNPs were genotyped (see ‘Online Supporting Information’) allowing for the 
definition of the MAPT H1/H2 haplotypes and the APOE ε2/ε3/ε4 genotypes.   
 
Statistical Analysis  
 
Univariate comparisons between two groups [Dementia (including DLB and PDD) vs. 
PDND] were made using the t-test for independent samples or Fisher Exact test whilst, for 
comparisons between three groups (DLB, PDD and PDND), we used one way ANOVA 
followed by Fisher’s Least Significant Difference Test (with Bonferroni correction for 
multiple comparisons). We used Pearson product-moment correlation analysis to evaluate 
correlations between specific variables of interest.  
Univariate regression models were used to search for possible predictors of dementia, 
latency to dementia or higher neuropathological scores. We used logistic regression for 
binary outcomes (dementia) and linear regression for continuous outcomes 
(neuropathological scores, latency to dementia), all of which were adjusted for gender and 
age at death. Univariate regression analysis was followed by construction of multivariate 
models to explore the simultaneous effects of the factors that were significantly associated 
with dementia when analysed individually.  
Kaplan Meier plots for survival analysis were generated, using a Cox Proportional 
Hazard model, to evaluate the effect of pathology on time to dementia (latency to dementia 
from onset of motor signs) by comparing high versus low scores of neuropathological 
staging. Receiver Operator Characteristic (ROC) curves were constructed to evaluate the 
ability of pathology (LB, tau, Aβ plaques or their combination) to predict dementia based on 
logistic regression (for more information see ‘Online Supporting Information’).  
Significance was set at a p-value of 0.05, with Bonferroni correction in case of multiple 
testing in the same analysis.  All analyses and graphs were carried out with R 2.15.3 (R 
Foundation for Statistical Computing).54 
 
 
RESULTS 
 
The basic demographic, clinical, neuropathological and genetic characteristics of our 
sample are summarised in Tables 1 and 2. The mean age at death of our sample was 77.8 
± 7.4 years (range 58 – 93) and the mean age at onset of PD signs was 65.6 ± 9.7 years 
(range 40 – 86), with a mean disease duration of 12.2 ± 6.9 years (range 0 – 29). The 
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mean age of dementia onset was 71.7 ± 7.5 years in DLB and 74.6 ± 6.8 years in PDD. 
More information on clinical, neuropathological and genetic characteristics of the sample is 
available in the ‘Online Supporting Information’.  
 
Neuropathology of Dementia 
 
All LB scores (both the regional and the overall cortical mean) and the proportion of 
cases with αSN-Braak stage 6 were significantly higher in the dementia groups (DLB and 
PDD) compared to PDND (Table 2 and Figure 1). Furthermore, a higher CLB load was 
observed in the temporal and parietal cortex in DLB compared to PDD (Fig 1b). We did not 
observe any significant difference across the three groups for Braak tau staging, with 84% 
of all cases being in the mild (Braak stage 0-II) category. Cortical and striatal Aβ plaque 
scores were significantly higher in DLB compared to PDD and in the dementia group as a 
whole (DLB + PDD) compared to PDND, but no difference was noted between PDD and 
PDND. Correlation analysis showed a positive correlation between tau staging, LB score 
and Aβ plaques (Table 3).   
The following neuropathological variables were associated with dementia in the 
univariate logistic regression models: SFC LB score (OR 2.65, p<0.0001); AC LB score 
(OR 2.45, p=0.001), TC LB score (OR 3.69, p<0.0001), PC LB score (OR 3.64, p<0.0014); 
EC LB score (OR = 2.04, p<0.001); mean Cortical LB score (OR 4.13, p<0.034); highest 
cortical Aβ plaque score (OR 1.85, p=0.001); total cortical Aβ plaque score (OR 1.40, 
p=0.001); αSN Braak stage (OR 3.23, p=0.034); and striatal Aβ plaque score (OR 2.58, 
p=0.005).. In the multivariate model, only the mean CLB score maintained a strong 
association with dementia (OR: 4.23, p<0.001) (Table 4).  
ROC curves indicated that the mean CLB score (AUC: 0.802; 95%CI:0.722-0.883) was 
the best indicator of the presence of dementia, and this was not improved when all three 
pathologies of tau, Aβ, and CLB were analysed together (AUC: 0.798; 95%CI: 0.717-
0.879) (Figure 3).  
 
Timing of Dementia 
 
Age of onset of dementia and latency of dementia from onset of motor signs were 
analysed using linear regression models. Among the neuropathological variables, only the 
LB scores in the parietal cortex were associated with an earlier age at onset of dementia 
(beta coefficient -4.66, p=0.004) and, among the demographic factors, women had a later 
age of onset than men (beta coefficient 6.96, p<0.001). A significant association of shorter 
 8
latency to dementia from the onset of motor signs was observed with the following 
neuropathological variables: tau topographical staging (beta = -3.91, p=0.004); total 
cortical (beta = -1.94, p=0.01) and striatal (beta = -2.97, p=0.006) Aβ plaque scores; AC LB 
score (beta = -2.21, p=0.04) and TC LB score (beta=-2.11, p=0.01).  When these variables 
were included in a multivariate model using stepwise linear regression, the total cortical Aβ 
plaque score emerged as the only independent predictor of latency to dementia (beta =-
1.37, p<0.001). No association was observed between CVP and the age of onset of 
dementia or the latency of dementia from onset of motor signs.   
Survival analysis, with time to dementia (or death) as the time variable and dementia as 
the outcome, showed that the sum of CLB scores from all 5 regions was a good predictor 
of a faster progression to dementia (OR=3.08, p<0.01; Fig 4b). Higher Aβ scores also 
predicted a faster progression to dementia (OR 1.19, p=0.02; Figure 4a) but neither higher 
Braak αSN stages nor higher Braak tau stages did (p = 0.20, and p = 0.55, respectively, 
Figure 4c and 4d).  
 
 
Genetics of Dementia  
 
There were no significant differences between patients with and without dementia in the 
proportion of either APOE ϵ4 allele carriers (Fisher’s Exact Test, p=0.16) or H1/H1 
haplotype carriers (Fisher’s Exact Test, p=0.64). However, when the dementia group was 
subdivided into DLB and PDD, a non-significant trend for a higher prevalence of the APOE 
ϵ4 allele was observed in DLB (Fisher’s Exact Test, p=0.06). 
The association between APOE ϵ4 allele carrier status and cortical Aβ plaque burden 
was significant (t=2.31, p=0.02; Figure 5a) in the overall sample. Furthermore, there was a 
strong correlation between carrying at least one APOE ϵ4 allele and having a higher 
cortical LB burden (t=3.38, p=0.001). This finding was confirmed in the multivariate model 
(covariates: age at death, gender, total cortical Aβ score), using linear regression analysis 
(standardized beta: 0.187, p=0.02), where total cortical Aβ score also emerged as a 
significant predictor of a higher cortical LB burden (standardized beta: 0.487, p<0.01). 
Linear regression, with individual regional cortical LB scores as the dependant variable 
and APOE ϵ4 carrier status as the independent variable, showed that the ϵ4 allele was 
associated with higher LB scores in the superior frontal (beta coefficient 0.73, p<0.001), 
parietal (beta coefficient 0.68, p=0.003) and temporal (beta coefficient 0.71, p=0.006) 
cortex but not in the anterior cingulate or entorhinal cortex (Figure 5b).  
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There was no correlation between APOE ϵ4 carrier status and higher tau stages, or 
between MAPT H1/H1 status and any of the clinical or neuropathological variables. 
 
 
DISCUSSION 
 
We have conducted an integrated retrospective analysis of clinical, pathological and 
genetic characteristics of DLB, PDD and PDND in one large sample of patients - tissue 
donors to the Parkinson’s UK Brain Bank. Our findings confirm the previously reported 
strong positive association between CLB burden and the presence of dementia in PD.6,11-
14,18,20
 CLB burden was higher in all five examined brain regions in patients with dementia 
(both DLB and PDD) compared to PDND individuals. This finding implies a widespread 
increase of cortical pathology in Lewy body dementias12,14,18 rather than a selective 
deposition of cortical LB in the frontal and temporal neocortical regions as previously 
reported.33,55 However, we did observe a higher CLB burden in the parietal and temporal 
cortex in DLB compared to PDD. Furthermore, our univariate analysis showed a significant 
correlation between the temporal LB load and the latency to dementia from the onset of 
motor signs and indicated that parietal LB scores were an independent predictor of a 
younger age at onset of dementia. Taken together, these findings support the hypothesis 
that higher CLB burden in the neocortical parietal and temporal cortex may, at least partly, 
account for the short latency (or lack thereof) between the onset of motor signs and 
dementia in DLB compared to PDD. Interestingly, a recent study reported higher overall 
pathological scores in the temporal cortex as a distinguishing characteristic of DLB 
cases.30  
DLB cases were also characterized by a higher cortical and striatal Aβ plaque burden 
compared to PDD, in agreement with previous studies (Figure 2b).24-26,28 Although we 
observed a trend suggesting a greater striatal Aβ plaque density in PDD compared to 
PDND, this difference did not reach statistical significance in our sample. A higher 
proportion of DLB cases with a moderate-high Aβ burden compared to PDD has been 
reported (87% and 43%, respectively) together with an inverse correlation between cortical 
burden of both LB and Aβ plaques and time to dementia in a sample of DLB and PDD 
cases.24 In vivo amyloid [11C] PIB PET studies have also shown a higher Aβ plaque load 
in DLB compared to PDD.56-57 In our multivariate model using stepwise linear regression, 
the total cortical Aβ plaque burden was the only independent predictor of shorter latency to 
dementia from onset of motor signs. This finding is in keeping with results from 
neuropathological analysis of a longitudinally followed cohort of PD cases with and without 
dementia. In this study, Halliday and coworkers reported a higher prevalence of significant 
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Aβ plaque pathology in cases with early onset of dementia (DLB) than that found in cases 
with a long disease duration and late onset cognitive impairment (PDD).58 Finally, survival 
analysis indicated that CLB burden is also a good predictor of faster progression to 
dementia (Figure 4).  
 We confirm the previously reported positive correlation between CLB pathology and 
neuropathological features of AD in DLB and PDD.12,20,21,32-34  However, the precise 
mechanism of this dynamic interaction cannot be elucidated solely through post-mortem 
studies. Disentangling the respective roles of these pathologies in DLB and PDD is further 
confounded by their relatively frequent occurrence in post-mortem studies of asymptomatic 
elderly individuals.18,19,36,59 Of note, our analysis with ROC curves showed that CLB 
pathology by itself is the best predictor of dementia and that the combination of all three 
pathologies does not improve the area under the curve, which supports the dominant role 
of αSN deposition in the development of dementia in PD (Figure 3).  
The finding of a similar age at onset of dementia and a similar interval between 
dementia onset and death in our series of patients with DLB and PDD is in agreement with 
the concept of a non-linear disease progression, with milestones such as dementia 
heralding a stereotyped final phase of the disease, notwithstanding differences in the 
overall disease duration.60 Whilst disease progression in PDD seems to conform to the 
Braak staging theory of a predictable order of ascending caudo-rostral αSN deposition,61 
the timing of dementia in relation to the onset of motor signs in DLB is intriguingly 
discordant to this staging model.  Progression of αSN pathology in DLB seems to follow a 
different and/or much faster ‘map’ of regional propagation, compared to PDD and PDND. 
Indeed, DLB is said to reside at the most severe end of the Lewy body disease spectrum, 
with “incidental LBD” at the other end.10 Comorbid occurrence of Aβ and αSN in 
neocortical regions in DLB may give rise to reciprocal promotion of fibrillization, as has 
already been shown to occur in vitro,62-63 thus initiating or accelerating the 
neurodegenerative cascade with progressive involvement of more caudal regions. This 
could account for the “inverse” clinical progression in DLB compared to PDND and PDD. 
In our sample, the MAPT H1/H1 haplotype was not associated with dementia. 
Furthermore, in contrast with previous reports, we found no correlation between the MAPT 
H1/H1 and any of the neuropathological markers.35,39 In our study, the overall prevalence 
of moderate or severe Braak tau stages (III – VI) was low (16%) and did not differ 
significantly between LBD patients with and without dementia. Thus, at variance with some 
studies21-22,60 and in agreement with others,11,13,23 we can only conclude that tau pathology 
(a key determinant of AD) does not seem to have an independent role in the occurrence of 
cognitive decline in LB disease. A recent report on the frequency of APOE ϵ4 in a large 
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series of AD+ and AD- synucleinopathies with dementia has indicated an increased 
frequency of ϵ4 in all forms, even in the absence of AD pathology.36 We did not observe a 
direct effect of the APOE ϵ4 allele on dementia in our sample.  
Interestingly, the APOE ϵ4 allele was associated with higher cortical Aβ plaque 
pathology and was strongly associated with high CLB burden, particularly in neocortical 
regions. Multiple linear regression adjusting for AD pathology did not alter the significant 
association between the APOE ϵ4 allele and CLB burden. Thus, the APOE ϵ4 allele may 
mediate increased neocortical LB deposition either indirectly, possibly through a greater 
abundance of fibrillization-promoting Aβ plaques, or directly through yet unexplored 
mechanisms. Gearing and coworkers found a similar prevalence of the APOE ϵ4 allele 
when comparing cases with pure AD pathology to cases with AD associated with a 
pathologic diagnosis of PD (AD + PD). They reported an increase in neurite density in the 
CA2-3 regions of the hippocampus in AD+PD cases, which correlated with APOE ϵ4 
dosage. They did not however demonstrate a significant increase in cortical Lewy 
pathology with increasing APOE ϵ4 dosage, although there was a trend in that direction.64 
Similarly, in a small sample of pure LBD cases, Lippa and colleagues found more intense 
neuritic degeneration in the CA2-3 regions in APOE ϵ4 carriers but no association between 
APOE ϵ4 allele and density of cortical pathology.65 Both of these studies pre-dated the 
advent of alpha-synuclein-reactive antibodies and were based on ubiquitin staining, which 
may have caused underestimation of Lewy pathology.64-65 More recently, the study by 
Compta and colleagues failed to find any correlations between APOE ϵ4 allele and cortical 
Lewy body density, in a large sample comparing PD cases with and without dementia.20 
On the other hand, Mattila and co-workers reported greater numbers of Lewy bodies in 
several cortical regions in APOE ϵ4 carriers in a post-mortem PD cohort, compared to 
subjects without the APOE ϵ4 allele. However, they did not assess whether this held true 
after adjusting for concomitant AD pathology, which was present in 40% of cases in their 
sample.33 More recently, Irwin and and colleagues reported a multivariate model in which 
both the APOE ϵ4 allele and cortical tau pathology predicted a higher CLB burden.14 We 
have confirmed this, enforcing the concept that the APOE ϵ4 allele may have an 
independent role in increasing CLB burden, and we have extended these findings to 
include DLB cases. Furthermore, our linear regression models for each analysed cortical 
region point to the neocortical frontal, temporal and parietal regions as the site where the 
APOE ϵ4 allele might exert its influence on CLB, as opposed to the allocortical cingulate 
and entorhinal cortex, where this association was not seen.  
This study has several limitations. In common with all retrospective studies, clinical 
symptoms and signs may have been underreported, due to negative ascertainment bias, 
resulting in potential errors of approximation of the timing of onset and duration of 
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symptoms but with little impact on the genetic-pathological correlations. Furthermore, 
neuropathological analysis of post-mortem data is not the appropriate methodology to 
evaluate the dynamic process of disease progression in DLB and PDD. Longitudinal 
neuroimaging studies using clinically validated  αSN markers,66 if and when they become 
available, would be a more suitable approach in this respect. Also, there was some 
asymmetry in sample size, with smaller numbers of DLB cases compared to the other two 
groups. This was due to our approach to case selection, which was based on a 
neuropathological diagnosis and unbiased towards the occurrence of dementia. Our 
sample was derived from donors to a movement disorders brain bank. Thus, our DLB 
cases were more likely to have parkinsonian syndromes and may represent a subtype of 
DLB. Finally, subjective semiquantitative assessment of pathology visualized with 
immunohistochemical techniques may have failed to capture more subtle effects of 
regional pathology. For example, our finding of a lack of association between the burden of 
fibrillary tau pathology and dementia is based on the established Braak staging scheme, 
which may fail to capture small but potentially significant differences in entorhinal 
pathological tau burden between cases with the same Braak score. Further studies based 
on computerized quantitative assessment of pathology can be expected to substantiate 
and refine our findings.67 The main strength of our report resides in our integrated 
approach combining clinical, neuropathological and genetic analysis to study one large 
sample of PD patients with and without dementia of the DLB and PDD forms.  
In summary, our data provide further support to the notion that neocortical LB burden is 
the key neuropathological substrate of DLB and PDD, and we report a strong association 
of a higher neo-cortical LB pathology with APOE ϵ4, which remains significant after 
adjusting for Aβ pathology. DLB shares important features with AD in the form of prominent 
Aβ (but not tau) pathology and APOE ϵ4 status and may represent a biological link 
between the two nosological entities of AD and PD. Further studies are required to better 
elucidate the modalities of interactions between αSN and Aβ, as well as the modulating 
mechanism of APOE ϵ4 on LB neocortical pathology.  
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TABLE 1: Clinical, genetic and demographic characteristics 
 DLB (n = 17) PDD (n = 55) PDND (n = 49) Dementia (n=72)a  
Females 3 (18%) 17 (31%) 15 (31%) 20 (28%) 
Age at death (yrs) 75.88 ± 7.30 77.69 ± 6.63 78.53 ± 8.19 77.26 ± 6.78  
Age at onset motor (yrs) 71.41 ± 7.66c 62.95 ± 8.75 66.47 ± 10.45 64.94 ± 9.20 
Disease duration (yrs) 4.47 ± 1.87b d 14.75 ± 6.10 12.06 ± 6.72 12.32 ± 6.96  
Age onset dementia (yrs) 71.76 ± 7.47 74.60 ± 6.80 - 73.93 ± 7.01 
Time to dementia (yrs) 0.35 ± 0.49 d 11.65 ± 5.39 - 8.99 ± 6.74 
Dementia duration (yrs) 4.12 ± 1.76 3.09 ± 2.26 - 3.33 ± 2.21 
Hallucinations  14 (82%) b 48 (87%) f 9 (18%) 62 (86%) g 
RBD  10 (59%) b c  15 (27%) e 5 (10%) 25 (35%) g 
Cognitive Fluctuations  5 (33%) b 11 (20%) f 0 (0%) 16 (22%) g 
APOE4 carrier   7 (47%) 18 (33%) 11 (22%) 25 (35%) 
MAPT H1/H1 10 (67%) 38 (69%) 30 (61%) 48 (67%) 
yrs: years; RBD: REM sleep Behavior Disorder; a DLB + PDD; b vs PDND p <0.001; c vs PDD p < 0.05; d vs 
PDD p < 0.001; e vs PDND p < 0.05; f vs PDND p < 0.001; g vs PDND p < 0.001. 
Dementia was compared to PDND with Mann-Whitney U test or Chi Square test, as appropriate. The three 
groups of DLB, PDD, and PDND were compared with One Way Anova, followed by Fisher’s Least 
Significant Difference, with Bonferroni correction for multiple testing. 
Values are expressed as either counts (%) or mean ± SEM. 
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TABLE 2: Neuropathologic Characteristics 
 DLB PDD PDND Dementia a  
αSN Braak Stage VI 16 (94%) 52 (95%) 40 (82%) 68 (94%) g 
αSN Braak Stage V 1 (6%) 3 (5%) 6 (12%) 4 (6%) 
αSN Braak Stage III/IV 0 0 3 (6%) 0 
Tau Severe (Braak V-VI) 4 (24%) 1 (2%) 1 (2%) 5 (7%) 
Tau Moderate (Braak III-IV) 3 (18%) 6 (11%) 4 (8%) 9 (13%) 
Tau Mild (Braak 0-II) 10  (58%) 48 (87%) 44 (90%) 58 (80%) 
SFC LB Score 2.41 ± 1.12 c 1.86 ± 1.04 f 1.10 ± 0.71 1.99 ± 1.07 h 
AC LB Score 2.81 ± 0.54 b 2.60 ± 0.85 e 2.00 ± 0.89 2.66 ± 0.78 h 
TC LB Score 2.57 ± 0.76 c d 1.61 ± 1.08 f 0.75 ± 0.63 1.87 ± 1.09 h 
PC LB Score 1.91 ± 1.14 c d 1.09 ± 0.90 e 0.44 ± 0.60 1.26 ± 1.02 g 
EC LB Score 2.47 ± 0.83 c 2.36 ± 1.09 e 1.52 ± 1.11 2.38 ± 1.02 h 
Mean Cortical LB Score 2.51 ± 0.68 c 2.03 ± 0.87 f 1.22 ± 0.67 2.14 ± 0.85 h 
Striatal Aβ Plaque Score 2.43 ± 1.13c d 1 ± 1.14  0.52 ± 0.98 1.40 ± 1.29 g 
Frontal Aβ Plaque Score 2.24 ± 0.90 c d 1.27 ± 1.10 0.80 ± 0.93 1.51 ± 1.12 h 
Ent. Aβ Plaque Score 2.06 ± 1 c d 1.11 ± 0.91 0.78 ± 0.92 1.34 ±1.00 g 
Total Aβ Plaque Score 4.13 ± 1.85 c d 2.43 ± 1.92e 1.57 ± 1.79 2.81 ± 2.02 g 
CVP 3 (18%) 20 (36%) 14 (29%) 23 (32%) 
LB: Lewy body; SFC: superior frontal cortex; AC: anterior cingulate; TC: temporal cortex; PC: parietal cortex; 
EC: entorhinal cortex; HC: Highest Cortical; CVP: Concomitant Vascular Pathology. 
a
 DLB + PDD; b vs PDND p < 0.05; c vs PDND p < 0.001; d vs PDD p < 0.05; e vs PDND p < 0.05; f vs PDND 
p < 0.001; g vs PDND p < 0.05; h vs PDND < 0.001.  
Dementia was compared to PDND with Mann-Whitney U test or Chi Square test, as appropriate. The three 
groups of DLB, PDD, and PDND were compared with One Way Anova, followed by Fisher’s Least 
Significant Difference, with Bonferroni correction for multiple testing.  
Values are expressed as either counts (%) or mean ± SEM. 
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TABLE 3: Pearson correlation analysis (taken as all possible pairs) of the three types of 
pathologies across the whole sample (DLB, PDD and PDND).  
 
 Braak αSN 
stage 
Braak tau 
stage 
Mean 
Cortical LB 
score 
Striatal Aβ 
score 
Cortical Aβ 
score 
Braak αSN stage 
r 
P-value 
1 
- 
0.12 
0.18 
0.44 
<0.001 
-0.07 
0.64 
0.03 
0.71 
Braak tau stage 
r 
P-value 
 
 
1 
- 
0.35 
<0.001 
0.46 
0.001 
0.44 
<0.001 
Mean Cortical LB 
score 
r  
P-value 
  1 
- 
0.48 
<0.001 
0.54 
<0.001 
Striatal Aβ score 
r 
P-value 
   1 
- 
0.85 
<0.001 
Cortical Aβ score 
r  
P-value 
   
 1 
- 
R = correlation coefficient; correlation is significant for p-values < 0.05. 
 
 
TABLE 4: Neuropathological variables associated with dementia 
Univariate Regression 
Variable OR CI P-value 
SFC LB score 2.65 1.75 – 4.27 <0.0001 
TC LB score 3.69 2.15 – 6.90 <0.0001 
PC LB score  3.74 1.96 – 7.92 <0.0014 
AC LB score 2.45 1.53 – 4.20 =0.001 
EC LB score 2.04 1.44 – 2.99 <0.001 
Mean CLB score 4.13 2.45 – 7.52 <0.034 
HC Aβ score 1.85 1.26 – 2.64 =0.001 
Total Cortical Aβ score 1.40 1.13 – 1.69 =0.001 
αSN Braak stage 3.23 1.30 – 11.79 =0.034 
Striatal Aβ score 2.58 1.40 – 5.42 =0.005 
Multivariate Regression 
Mean CLB score 4.23 2.19 – 8.98 <0.001 
LB: Lewy body; SFC: superior frontal cortex; AC: anterior cingulate; TC: temporal cortex; PC: parietal 
cortex; EC: entorhinal cortex; HC: Highest Cortical; CLB: Cortical Lewy body.  
In the multivariate logistic regression model, we included the mean CLB score rather than the individual 
regional LB scores and the total cortical Aβ plaque score to circumvent collinearity issues of LB load in 
the 5 cortical regions and of the Aβ burden between the frontal and entorhinal regions, respectively. 
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Figure Captions 
 
FIGURE 1: Distribution of mean overall (a) and regional (b) cortical Lewy body scores. DLB 
is in solid grey, PDD in white and PDND in striped bars.   The columns represent mean 
values ± SEM.  Asterisks denote significance level (* p < 0.05; ** p < 0.01). SFC: superior 
frontal cortex; AC: anterior cingulate; TC: temporal cortex; PC: parietal cortex;  EC: 
entorhinal cortex.  
 
FIGURE 2: Distribution of (a) highest cortical (highest between entorhinal and frontal 
region) and (b) striatal Aβ plaque scores with semi-quantitative staging (0 = none, 1 = mild, 
2 = moderate, 3 = severe). DLB is in solid grey, PDD in white and PDND in striped bars, 
while both dementia types (DLB and PDD) grouped together are in slate. The columns 
represent mean values ± SEM. Asterisks denote significance level (* p < 0.05; ** p < 0.01, 
*** p < 0.001).   
 
FIGURE 3: Receiver Operator Characteristic (ROC) curves for ability of pathology to 
classify LBD cases in those with and without dementia, as estimated by logistic regression 
models, with dementia as outcome and the three pathologies as covariates, individually 
(a,b,c) or jointly (d). (a) Mean CLB score AUC: 0.802; 95%CI:0.722-0.883; (b) Braak tau 
score AUC: 0.548; 95%CI; 0.485-0.610; (c) Total Cortical Aβ AUC: 0.666; 95%CI: 0.571-
0.761; (d) Combined pathologies AUC: 0.798; 95%CI: 0.717-0.879. AUC = Area under 
Curve, which is equal to the probability that the explanatory variable correctly identifies 
dementia cases (AUC of 50% correspond to a random finding). The neuropathological 
variable with the highest predictive value was the mean CLB score (a); the predictive 
ability of the model did not increase when the three pathologies were analysed together 
(d).  
 
FIGURE 4: Kaplan-Meier survival analysis curves, using a Cox proportional hazard model, 
with dementia as outcome and neuropathological scores as predictors. (a) Sum of semi-
quantitative Aβ cortical plaque scores:  score of 0 to 3 vs. score of 4 to 6. Higher Aβ scores 
predicted a faster progression to dementia (OR 1.84, 95%CI: 1.14-2.97; p=0.01); (b) Total 
cortical LB score (sum of 5 cortical regions): overall score ≤ 9 vs score ≥ 10. A higher CLB 
score was a good predictor of earlier dementia (OR 3.85, 95%CI: 2.31-6.42; p<0.001); (c) 
Braak tau staging: stage ≥ III vs stage ≤ II. (OR 1.69, p = 0.08). (d) Braak αSN staging: 
stage VI vs stage ≤ V (OR 2.40, p = 0.09).  
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FIGURE 5: a) Boxplot of Total Cortical Aβ score distribution comparing individuals carrying 
at least one APOE ϵ4 allele (homozygote or heterozygote) and individuals not carrying ϵ4 
at all.  b) Cortical LB score distribution across brain regions, comparing patients carrying at 
least one APOE ϵ4 allele (homozygote or heterozygote) and non-carriers of ϵ4. SFC: 
superior frontal cortex; AC: anterior cingulate; TC: temporal cortex; PC: parietal cortex;  
Ent: entorhinal cortex; for both panels E4 = ϵ4 
 
 
 
FIGURE 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 27
FIGURE 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 28
 
FIGURE 3 
 
 
 
 
 
 
 
 
 
 
 29
 
FIGURE 4 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 30
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